FDA Cancels Merck’s Sugammadex NDA Advisory Panel Meeting

Merck received news that the FDA cancelled a previously scheduled meeting with the Anesthetic and Analgesic Drug Products Advisory Committee, intended to consider Merck's resubmitted new drug application (NDA) for sugammadex.

Source: Pharma Manufacturing
More...